Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals

What happened

Angelini Pharma announced the completion of its acquisition of Catalyst Pharmaceuticals, supported by Blackstone and a €1 billion investment from CDP Equity, expanding Angelini's U.S. presence in brain health and rare diseases. The transaction provides Catalyst shareholders with a cash exit, likely at a premium to the prior trading range of around $21.39. The DeepValue report had rated Catalyst a BUY based on its undervaluation at ~12x earnings, net cash balance sheet, and a durable rare-disease portfolio with FIRDAPSE, FYCOMPA, and AGAMREE. With the acquisition, the standalone thesis of portfolio growth and capital returns is replaced by a realized takeout value, eliminating both upside and downside risks associated with execution and generic competition. Investors should confirm the final per-share consideration and assess whether it approaches the DCF-based intrinsic value of $108.30 or reflects a more conservative premium.

Implication

For holders, this is a liquidity event; the thesis now hinges on whether the offered price is fair relative to the company's intrinsic value of $108.30 per DCF estimates. If the price is significantly below, appraisal rights may be considered, but otherwise, the event closes the standalone investment case.

Thesis delta

The prior BUY thesis was predicated on Catalyst's independent growth, undervaluation, and capital returns. The completion of the acquisition by Angelini Pharma validates the company's asset value but eliminates the potential for further standalone upside. The investment narrative shifts from operational execution to evaluating the fairness of the acquisition consideration, making the prior thesis no longer applicable.